# Safety
Keywords: SPINRAZA, spinal muscular atrophy, lumbar puncture, adverse reactions, clinical studies, immunogenicity, contraindications

> This page provides detailed information about the safety profile of SPINRAZA, including adverse reactions, clinical study data, post-marketing experience, and special warnings for its administration.

## Details
- [Adverse Reactions](#): Adverse reactions related to SPINRAZA administration via lumbar puncture, including headache, vomiting, and back pain, are discussed.
- [Clinical Studies](#): The safety of SPINRAZA was assessed in Phase III and open-label studies involving infants and children with SMA.
- [Post-Marketing Experience](#): Reports of serious infections, such as meningitis, and other adverse reactions observed in post-marketing settings are highlighted.
- [Special Warnings](#): Precautions for lumbar puncture procedures, thrombocytopenia, renal toxicity, hydrocephalus, and immunogenicity are provided.
- [Contraindications](#): Lists hypersensitivity to the active substance or specific excipients as contraindications for SPINRAZA use.